The DYNC1LI1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma line, designed for targeted disruption of the DYNC1LI1 gene. This product provides a loss-of-function model to study cytoplasmic dynein 1 light intermediate chain 1 functions. The heterogeneous pool of edited cells offers a stable genetic background without clonal biases, suitable for investigating dynein-mediated processes.
A-549 cells are a well-established model of non-small cell lung cancer, originating from alveolar basal epithelial cells with adherent morphology. They retain active EGFR signaling and other pathways relevant to tumorigenesis, and are widely employed for drug response studies and mechanistic cancer research. This host line enables analysis of motor protein contributions to NSCLC biology.
DYNC1LI1 encodes a light intermediate chain subunit of cytoplasmic dynein 1, a multi-component motor complex that drives minus-end-directed transport of organelles and vesicles along microtubules. It interacts with regulatory factors DCTN1, PAFAH1B1, BICD2, and NDEL1, facilitating dynein processivity. Within the complex, DYNC1LI1 associates with heavy chain DYNC1H1 and light chains DYNC1I2, DYNLRB1, and DYNLT1. These interactions are essential for autophagosome maturation, mitotic spindle assembly, and intracellular distribution of lysosomes and Golgi. Disruption of DYNC1LI1 compromises retrograde trafficking, autophagy, and chromosome segregation.
In A-549 lung adenocarcinoma cells, DYNC1LI1 knockout impairs EGFR endocytic trafficking and lysosomal degradation, leading to sustained downstream signaling through MAPK/ERK and PI3K/AKT pathways, which are frequently hyperactivated in NSCLC. Dynein dysfunction also disrupts lysosome positioning and autophagic flux, altering cellular stress responses. Moreover, mitotic spindle defects can drive chromosomal instability, a hallmark of cancer progression. This model is thus instrumental for dissecting dynein’s role in tumor cell biology.
This polyclonal knockout pool is suited for diverse experiments: live-cell tracking of lysosomal and endosomal movements, immunofluorescence for LAMP1 and GM130 to assess organelle positioning, Western blotting to confirm DYNC1LI1 depletion and dynein complex integrity, flow cytometry for cell cycle analysis, and wound-healing assays for migration. Drug sensitivity testing with agents like paclitaxel and cisplatin helps evaluate chemoresistance mechanisms. For further details, please contact Ascent Research.
